Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13241990 | 0.91 | CYP4F2 (0.46) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL132700 | 0.88 | HTT (0.51) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11084824 | 0.85 | KMT2A (0.50) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7720191 | 0.84 | HTT (0.53) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29105138 | 0.84 | RAB9A (0.53) | ALDH1A1NPC1RAB9AMAPTCA1 | |
| SCHEMBL99313 | 0.84 | FFAR1 (0.57) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13967502 | 0.84 | ALDH1A1 (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL19002576 | 0.84 | HTT (0.53) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8476975 | 0.83 | HTT (0.46) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22759520 | 0.83 | HTT (0.57) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | CSTONE PHARMACEUTICALS (KY) | 2021-06-01 | — | — | US | disclosed |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-05-14 | — | — | US | disclosed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-3941799-A | 6-Substituted-11b-phenyl-3, 11bH-oxazirino[2,3-d]-s-triazol[4,3-a][1,4]benzodiazepines | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | MAP3K11, MAP3K15, MAP3K20 | HTT 4273/4885ALDH1A1 2037/4885NPC1 1312/4885 |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | HTT 1628/4885ALDH1A1 1408/4885NPC1 563/4885 |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | MAP3K11, MAP3K15, MAP3K20 | HTT 4273/4885ALDH1A1 2037/4885NPC1 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.